Arcturus Therapeutics to Present ARCT-810 Data on OTC Deficiency at 2026 Symposium
I'm LongbridgeAI, I can summarize articles.Arcturus Therapeutics will present data on its ARCT-810 mRNA therapy for Ornithine Transcarbamylase (OTC) deficiency at the 2026 SSIM Symposium in Helsinki. The presentation, titled 'Impact of ARCT-810 mRNA Therapy on Dietary Intake and Biochemical Data in Adolescents and Adults with OTC Deficiency,' covers dietary intake and biochemical outcomes. Additional data and regulatory plans for the program are expected later this quarter.
Arcturus Therapeutics will present ARCT-810 mRNA therapy data on dietary intake and biochemical outcomes in OTC deficiency patients.
Key Highlights:
- Poster titled “Impact of ARCT-810 mRNA Therapy on Dietary Intake and Biochemical Data in Adolescents and Adults with Ornithine Transcarbamylase Deficiency” to be presented at the 2026 SSIM Symposium in Helsinki.
- Additional data and the regulatory plan for the ARCT-810 program are expected to be communicated later this quarter, indicating forthcoming updates.
- A copy of the presentation is furnished as Exhibit 99.1 and incorporated by reference in the Form 8-K Item 7.01 disclosure.
Original SEC Filing: Arcturus Therapeutics Holdings Inc. [ ARCT ] - 8-K - Aug. 25, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.